Cody Shinavier
Psychiatric/Mental Health · Clarkston, MINPI 1952878092
Payments from drug & device makers
Across 894 payments — averaging $45.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$21K
- Teva Pharmaceuticals USA, Inc.$8K
- Otsuka America Pharmaceutical, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- AbbVie$1K
- Neurocrine Biosciences, Inc.$1K
- plus $6K from 18 others
What the payments were for
- Speaking & faculty fees$24,21859%
- Travel & lodging$2,0115%
- Food & beverage$14,33735%
- Education$2681%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 103 | $21,187 |
| Teva Pharmaceuticals USA, Inc. | 86 | $7,867 |
| Otsuka America Pharmaceutical, Inc. | 118 | $1,854 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 127 | $1,655 |
| AbbVie | 70 | $1,028 |
| Neurocrine Biosciences, Inc. | 50 | $1,015 |
| Johnson & Johnson | 41 | $1,001 |
| Corium, LLC | 40 | $795 |
| Takeda Pharmaceuticals U.S.A., Inc. | 45 | $645 |
| Vanda Pharmaceuticals Inc. | 34 | $619 |
| Alkermes, Inc. | 30 | $593 |
| Ironshore Pharmaceuticals Inc. | 34 | $532 |
| Axsome Therapeutics, Inc. | 16 | $452 |
| Lundbeck LLC | 21 | $384 |
| E.r. Squibb & Sons, L.L.C. | 25 | $353 |
| Collegium Pharmaceutical, Inc. | 25 | $306 |
| Indivior Inc. | 6 | $159 |
| Idorsia Pharmaceuticals US Inc | 9 | $130 |
| Noven Therapeutics, LLC | 5 | $88 |
| Sunovion Pharmaceuticals Inc. | 4 | $64 |
| Tempus AI, Inc | 2 | $49 |
| Almatica Pharma LLC | 1 | $25 |
| Biogen | 1 | $21 |
| Brainsway USA Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$19,571
- UZEDY$6,766
- INVEGA SUSTENNA$215
- VRAYLAR$124
- INGREZZA$121
- Auvelity$121
- Austedo XR$114
How this compares
$40,834 in reported general payments places this provider in the 95th percentile of 638 psychiatric/mental health providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 39 | $55,451 |
| RexultiBrexpiprazole | 11 | $18,538 |
| TrintellixVortioxetine Hydrobromide | 28 | $12,638 |
| VyvanseLisdexamfetamine Dimesylate | 16 | $4,876 |
| Duloxetine Hcl | 82 | $1,323 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 22 | $950 |
| Buspirone Hcl | 47 | $909 |
| Trazodone Hcl | 52 | $896 |
| Clozapine | 13 | $785 |
| Fluoxetine Hcl | 42 | $683 |
| Lurasidone Hcl | 14 | $682 |
| Lorazepam | 42 | $564 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 24 | $544 |
| Aripiprazole | 26 | $534 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 15 | $523 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $1,028 | $55,45139 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,854 | $18,53811 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $645 | $17,51444 claims |
| Almatica Pharma LLCSertraline Hcl | $25 | $13945 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 638 psychiatric/mental health providers in Michigan.
Other psychiatric/mental health in Clarkston
- Shiba NixonClarkston$60K
- Katherine WindrimClarkston$11K
- Mayche Vang-KueClarkston$6K
- Duren GutierrezSouthfield$207K
- Tamlynn EvansTraverse City$78K
- Amy AmesClinton Township$43K
- Oksana LidkeBattle Creek$30K
- Jennifer Wims-MaddenPontiac$28K
- Jessica ShantzWarren$21K
- Gladys KimeliSaginaw$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.